Human Beta-Defensin 1
Evidence: CAntimicrobial / Innate-Defense Peptides
Evidence Snapshot
What this grade covers
Composite proposed grade: identity/expression B; oxidized-form antimicrobial activity D (weak); reduced-form antimicrobial activity C (potent but single-source, unreplicated); human observational/disease-context C (single negative IBD finding). See claims for domain-specific detail -- do not read C as a single uniform grade.
Regulatory Context
Endogenous human peptide; no native hBD-1 drug product approval record identified in this review.
Research Takeaway
Human beta-defensin 1 (hBD-1) is a 36-amino-acid, three-disulfide-bond peptide encoded by DEFB1, originally isolated from human plasma.
Evidence boundary: Identity/discovery finding only. Does not itself establish any redox-state-specific activity.
See all 6 evidence claims →Quick Summary
Human beta-defensin 1 (hBD-1) is a constitutively-expressed human epithelial antimicrobial peptide that exists in two structurally distinct redox states with the same amino-acid sequence: an oxidized (disulfide-bonded) form with weak antimicrobial activity, and a reduced (linear) form with substantially more potent activity against Candida albicans and certain gut-commensal bacteria. This redox-dependent difference rests on a single primary study and has not been independently replicated.
Mechanism & Research Overview
Human beta-defensin 1 (hBD-1) is a constitutively-expressed human epithelial antimicrobial peptide that exists in two structurally distinct redox states with the same amino-acid sequence: an oxidized (disulfide-bonded) form with weak antimicrobial activity, and a reduced (linear) form with substantially more potent activity against Candida albicans and certain gut-commensal bacteria. This redox-dependent difference rests on a single primary study and has not been independently replicated.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Human beta-defensin 1 (hBD-1) is a 36-amino-acid, three-disulfide-bond peptide encoded by DEFB1, originally isolated from human plasma.
Does not establish
Evidence boundary: Identity/discovery finding only. Does not itself establish any redox-state-specific activity.
Supported
hBD-1 is constitutively expressed by epithelial tissue of the human urogenital tract and shows direct antimicrobial activity against E. coli in its classically-folded (oxidized) form.
Does not establish
Evidence boundary: Activity data here uses the oxidized/classically-folded form, not a redox-state comparison. Must not be presented as reduced-form evidence.
Sources: Human beta-defensin-1: an antimicrobial peptide of urogenital tissues
Supported
In its native, disulfide-bonded (oxidized) state, hBD-1 shows weak direct killing activity against Candida albicans and anaerobic Gram-positive commensals (Bifidobacterium, Lactobacillus species).
Does not establish
Evidence boundary: Single primary in vitro study. Does not represent hBD-1's full antimicrobial potential -- see the reduced-form claim below.
Sources: Reduction of disulphide bonds unmasks potent antimicrobial activity of human beta-defensin 1
Supported
Upon reduction of its three disulfide bonds, hBD-1 gains substantially more potent antimicrobial activity against the same organisms (C. albicans, Bifidobacterium, Lactobacillus).
Does not establish
Evidence boundary: SINGLE-SOURCE finding, not independently replicated in the current evidence base. Must not be described as replicated or confirmed by a second study.
Sources: Reduction of disulphide bonds unmasks potent antimicrobial activity of human beta-defensin 1
Supported
Living human intestinal and lymphoid cells can catalyze the reduction of extracellular hBD-1 via the thioredoxin (TRX) system, providing a plausible physiological mechanism for the oxidized-to-reduced conversion.
Does not establish
Evidence boundary: Supports the MECHANISM of conversion only -- does not independently confirm the potency comparison in the claim above.
Sources: Cell-mediated reduction of human beta-defensin 1: a major role for mucosal thioredoxin
Supported
Unlike hBD-2, hBD-1 was not found to be preferentially upregulated in the colonic mucosa of patients with inflammatory bowel disease.
Does not establish
Evidence boundary: Single study; a negative/boundary finding specific to hBD-1, not a statement about hBD-1's role in any other condition.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
The oxidized-vs-reduced antimicrobial potency comparison for hBD-1 rests on one primary study. No independent replication has been identified. This limitation should be treated as permanent rather than a pending gap.Safety Consideration
hBD-1's native, disulfide-bonded circulating form shows only weak direct antimicrobial activity in vitro -- a genuine limitation on the real-world relevance of the form as normally found.Safety Consideration
Unlike hBD-2, hBD-1 was not found preferentially upregulated in IBD colonic mucosa in the one study located -- stated here as a boundary finding to prevent an incorrect generalization from hBD-2's separate disease-association literature.
Research Areas Being Studied
Research areas discussed on this page reflect the Antimicrobial / Innate-Defense Peptides category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Cell-mediated reduction of human beta-defensin 1: a major role for mucosal thioredoxin (2013):
- Reduction of disulphide bonds unmasks potent antimicrobial activity of human beta-defensin 1 (2011):
- Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease (2002):
- Human beta-defensin-1: an antimicrobial peptide of urogenital tissues (1998):
- hBD-1: a novel beta-defensin from human plasma (1995):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Cell-mediated reduction of human beta-defensin 1: a major role for mucosal thioredoxin | 2013 | human intestinal and lymphoid cell lines/tissue | Living human intestinal and lymphoid cells can catalyze reduction of extracellular hBD-1 via the thioredoxin (TRX) system. | ||
| Reduction of disulphide bonds unmasks potent antimicrobial activity of human beta-defensin 1 | 2011 | recombinant human hBD-1; human epithelial/thioredoxin system | Oxidized hBD-1 shows weak antimicrobial activity; upon reduction of its three disulfide bonds, hBD-1 gains potent activity against Candida albicans and anaerobic Gram-positive commensals. | ||
| Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease | 2002 | human colonic mucosal biopsies (Crohn's disease, ulcerative colitis, unspecific colitis, controls) | Unlike hBD-2, hBD-1 was NOT preferentially upregulated in the colonic mucosa of IBD patients. | ||
| Human beta-defensin-1: an antimicrobial peptide of urogenital tissues | 1998 | human urogenital tissue; recombinant/native peptide in vitro | hBD-1 mRNA and peptide are expressed constitutively in human kidney and female reproductive tract epithelium; the classically-folded (oxidized) peptide is antimicrobial against E. coli. | ||
| hBD-1: a novel beta-defensin from human plasma | 1995 | human plasma, biochemical isolation | Original isolation and characterization of hBD-1 as a novel beta-defensin from human plasma: a 36-residue peptide with six cysteines forming three intramolecular disulfide bonds. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research on endogenous human beta-defensin 1 and does not constitute medical advice, a treatment recommendation, or dosing guidance for any related substance.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-29.
Follow research updates for Human Beta-Defensin 1
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.